Modulating the Gut Microbiome in Multiple Sclerosis Management: A Systematic Review of Current Interventions

• Published in: Journal of clinical medicine 2023-12, Vol.12 (24), p.7610
• Main Authors: Tsogka, Anthi, Kitsos, Dimitrios K, Stavrogianni, Konstantina, Giannopapas, Vasileios, Chasiotis, Athanasios, Christouli, Niki, Tsivgoulis, Georgios, Tzartos, John S, Giannopoulos, Sotirios
• Format: Article
• Language: English
• Subjects: Antigens; Autoimmune diseases; B cells; Biomarkers; Care and treatment; Case reports; Clinical medicine; Composition; Cytokines; Development and progression; Diagnosis; Diet; Digestive system; Disease; Fatigue; Feces; Health aspects; Immunology; Inflammation; Intervention; Lymphocytes; Medical research; Medicine, Experimental; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Multiple sclerosis; Nervous system; Neurodegeneration; Pathophysiology; Physiology; Probiotics; Systematic review
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12247610

This review attempted to explore all recent clinical studies that have investigated the clinical and autoimmune impact of gut microbiota interventions in multiple sclerosis (MS), including dietary protocols, probiotics, fecal microbiota transplantation (FMT), and intermittent fasting (IF). Thirteen studies were held between 2011 and 2023 this demonstrated interventions in gut microbiome among patients with MS and their impact the clinical parameters of the disease. These included specialized dietary interventions, the supply of probiotic mixtures, FMT, and IF. Dietary interventions positively affected various aspects of MS, including relapse rates, EDSS disability scores, MS-related fatigue, and metabolic features. Probiotic mixtures showed promising results on MS-related fatigue, EDSS parameters, inflammation; meanwhile, FMT-though a limited number of studies was included-indicated some clinical improvement in similar variables. IF showed reductions in EDSS scores and significant improvement in patients' emotional statuses. In dietary protocols, clinical MS parameters, including relapse rate, EDSS, MFIS, FSS, and MSQoL54 scales, were significantly improved through the application of a specific diet each time. Probiotic nutritional mixtures promote a shift in inflammation towards an anti-inflammatory cytokine profile in patients with MS. The administration of such mixtures affected disability, mood levels, and quality of life among patients with MS. FMT protocols possibly demonstrate a therapeutic effect in some case reports. IF protocols were found to ameliorate EDSS and FAMS scores. All interventional means of gut microbiome modulation provided significant conclusions on several clinical aspects of MS and highlight the complexity in the relationship between MS and the gut microbiome.